Many individuals at risk of streptococcal infection respond poorly to the pneumococcal polysaccharide vaccine Pneumovax 23. Identification of actionable pathways able to enhance Pneumovax responsiveness is highly relevant. We investigated the contribution of the extracellular adenosine pathway regulated by the ecto-nucleotidase CD73 in Pneumovaxinduced antibody responses. Using gene-targeted mice, we demonstrated that CD73-or A2a adenosine receptor deficiency significantly delayed isotype switching. Nevertheless, CD73-or A2aR-deficient adult mice ultimately produced antigen-specific IgG3 and controlled Streptococcus pneumoniae infection as efficiently as wild type (WT) mice. Compared to adults, young WT mice failed to control S. pneumoniae infection after vaccination and this was associated with lower levels of CD73 on innate B cells. We hypothesized that pharmacological activation of A2a receptor may improve Pneumovax 23 immunization in young WT mice. Remarkably, administration of the A2a adenosine receptor agonist CGS 21680 significantly increased IgG3 responses and significantly enhanced survival after S. pneumoniae challenge. Our study thus suggests that pharmacological activation of the A2a adenosine receptor could improve the efficacy of Pneumovax 23 vaccination in individuals at risk of streptococcal infection.
Introduction
Infections with S. pneumoniae are a major cause of morbidity and mortality in infants under 2 years of age, elderly patients and immunocompromised individuals [1] . Studies in mice demonstrated that antibodies produced by B-1a, B-1b and marginal zone (MZ) innate B cells play an important role in T cell-independent (TI) immune control of this pathogen both in naïve mice and in mice vaccinated with pneumococcal polysaccharides [2, 3] . B-1a B cells contribute mostly by producing natural IgM Ab, while B-1b B cells and MZ B cells in addition to producing IgM can also isotype switch and produce IgG (mainly IgG3). While the role of human counterparts of B-1 B cells in anti-pneumococcal immunity still remains controversial [4, 5] , several studies concluded that human B-1 B cells indeed constitute a major B cell population responding to Pneumovax 23 vaccination [4, 6] . While pneumococcal polysaccharide vaccination is effective in preventing S. pneumoniae infections, individuals who are at the highest risk of infection respond poorly to the Pneumovax 23 vaccine. For instance, elderly patients have a decreased B-1 B cell pool [7] and young infants are incapable of generating protective antibodies, suggesting impairment of Pneumovax specific B cells in these populations [8] . These observations stress the importance of identifying pathways and molecular targets which could be modulated therapeutically in order to enhance immune responses of these cells.
One of the important immune regulatory mechanism is through the production of extracellular adenosine by ecto-nucleotidases [9, 10] . Extracellular adenosine acts as a negative regulator of innate and adaptive immune responses and of inflammation. It exerts many of its immunoregulatory effects through the A2a receptor (one of the four adenosine receptors) and modulates multiple aspects of immune responses, including immune cell effector and regulatory functions, and cell homing [11, 12] . Therapeutic modulation of the adenosine pathway is an increasingly pursued avenue [9] . One of the rate-limiting enzymes in the generation of extracellular adenosine is CD73, a GPI-anchored or soluble nucleotidase that catalyzes the dephosphorylation of AMP into adenosine. Whether CD73-generated adenosine is involved in regulation of B-1 innate B cell responses to S. pneumoniae infection is currently unknown.
On one hand, engaging the CD73-adenosine pathway might be able to suppress potentially harmful inflammatory host responses during pneumococcal bacterial pneumonia, as recently reported [13] . On the other hand, CD73-derived adenosine may be required for effective antibody responses following vaccination. Accordingly, in vitro studies revealed that CD73 expression promotes class switch recombination in B-2 B cells [14] . Furthermore, because CD73 expression in lymphocytes is developmentally regulated, CD73 levels on B cells are low in young infants and in patients with common variable immunodeficiency, two patient populations highly prone to S. pneumoniae infections [14, 15] . The objective of this study was thus to investigate the importance of CD73 expression for innate B cell responses to S. pneumoniae following vaccination.
Murine B-1 B cells have been previously reported to express CD73 [16, 17] . We tested the hypothesis that CD73 potentiates antibody effector responses of B-1 B cells and responsiveness to Pneumovax 23 vaccination. Using CD73-deficient and A2a-deficient knockout (KO) mice, we report that the CD73-A2a adenosine receptor axis enhances early IgM to IgG3 isotype switch responses in innate B cells in vivo, but is not critical for the control of S. Pneumoniae challenge following Pneumovax 23 vaccination in mice. Importantly, we also demonstrate that administration of an A2a adenosine receptor agonist in young mice is sufficient to enhance IgM to IgG3 isotype switch following Pneumovax 23 vaccination and improve the control of S. pneumoniae infection.
Materials and methods

Mice
C57BL/6J WT mice were obtained from the Jackson Laboratory. C57BL/6N WT mice were maintained at the CRCHUM. CD73 KO (C57BL/6J background) and A2a KO (C57BL/6N) mice were obtained from Dr. Linda F. Thompson (Oklahoma Medical Research Foundation) and from Dr. Jiang-Fan Chen (Boston University School of Medicine) respectively and were maintained at the CRCHUM. Animals were housed in groups of 5 per cage. All experiments were approved by the Animal Protection Committee of the CRCHUM. were monitored for the development of the following clinical signs (dehydration, eye discharge, abnormally rapid breathing, hunched back, hypoactivity (grade 1: normal activity; grade 2: slight hypoactivity; grade 3 significant hypoactivity; grade 4: failure to move), lack of righting reflex, and response to stimuli). Monitoring was done every 12 hours for the first 24 hours, and subsequently every 6 hours or, if clinical signs or greater than 10% body weight loss were observed, every 3 hours. Body weight was monitored every 12 hours during the first day and subsequently every 6 hours. In case of dehydration, animals were given 0.1 ml of saline solution sub-cutaneously and wet pieces of food pellets were put inside the cage. Animals that showed markedly depressed ability to move (grade 3 and 4), with or without lack of righting reflex or lack of response to stimuli or markedly altered breathing were immediately sacrificed.
Antibodies and reagents
No animal death prior to reaching these clinical signs was observed, and no animals were found dead. Experiments were performed in an NC2 animal facility and all monitoring and manipulation of animals was done by NC2 trained personnel.
Enzyme-linked immunosorbent assays
ELISAs were performed according to a modified, previously published protocol [18] . For antigen-specific antibodies, nunc maxisorp plates were either coated overnight with pneumococcal polysaccharide type 3 (PPS3) (10 μg/ml), or Phosphorylcholine (PC)-BSA (5 μg/mL). For immunoglobulin levels, plates were coated overnight with goat anti-mouse IgG (10 μg/ml) or goat anti-mouse IgM (10 μg/ml). Blocking was done for 2 hours (200μL per well) at RT in PBS-0.1% Tween20-5% BSA. Samples were diluted in PBS-0.1% Tween20-0.1% BSA. For PPS3 ELISA, samples were preincubated for 60 minutes with CWPS (10μg/ml). Samples were plated overnight at 50 μL per well. HRP-conjugated anti-mouse IgM, IgG1, IgG2a, IgG2b, IgG3 and IgA detection antibodies (1:2000 dilution; Southern Biotech, Birmingham, AL) were added for 2 hours at room temperature (50 μL per well), followed by tetramethylbenzidine (TMB) substrate (50 μl per well). Reaction was stopped after 15 minutes with 2N hydrochloric acid (HCl) (50μl per well). Absorbance was read at 450 and corrected at 570 nm on a Versamax microplate reader. All steps were separated with washes (3X) made with PBS-0.1% Tween20. Samples were run in duplicates or triplicates. Analysis of ELISAs was done by determining OD (450-570). Each titer for a given mouse and ELISA was calculated as the inverse of the lowest dilution where OD readings are above 0.5 (at least 10-fold above background). Data from multiple experiments were analyzed by comparing the mean reciprocal titers of all mice included in WT, CD73 KO or A2a KO groups.
Immunofluorescence for gut IgA
Terminal ileum tissue was harvested from 8-week-old WT and CD73 KO mice, frozen in OCT media, sectioned on Superfrost Plus slides (Fisher; 12-550-15) and stored at -80˚C. Slides were thawed at room temperature for 30 minutes, fixed in 4% PFA, washed in PBS, blocked in DAKO protein blocker for 1 hour and stained with anti-mouse IgA primary antibody for 2 hours at room temperature. Sections were then washed in PBS and incubated with the FITCconjugated goat anti-rat IgG secondary antibody for 2 hours at room temperature. Slides were mounted with Prolong Gold plus DAPI (Invitrogen) and images were taken using a Nikon microscope with a X20 objective.
Statistical analysis
Data are shown as means +/-SEM. Statistics are performed by unpaired Student's T test or one-way ANOVA with Bonferroni correction when multiple comparisons were made and survival curves were assessed by the log-rank test.
Results
CD73 defines specific subsets of naïve and isotype-switched innate type B cells
We first evaluated CD73 expression in adult mouse B cells. Fig 1A) . Consistent with a role for CD73 in isotype class-switching [14] , the vast majority (~87%) of isotype-switched (IgG3 + ) B-1b B cells expressed CD73 (Fig 1A) . In young mice (3-week-old), however, the majority of B-1a and B1b B cells were negative for CD73 (Fig 1B) , consistent with prior reports of low CD73 expression on B cells from young infants [15] .
Normal B cell development and steady state antibody levels in CD73 KO mice
We next compared the steady-state levels of the various B cell subsets in adult WT and CD73-deficient (KO) mice. We observed no statistical difference in absolute numbers of B-1 and B-2 cells ( Table 1 ), supporting that CD73 is not required for their development. We next investigated the role of CD73 in innate B-1 B cell responses. B-1 B cells are the source of the natural antibody pool (e.g. anti-PC Ab targeting S. pneumoniae phosphorylcholine) [19] , and in this way, contribute to a major portion of serum IgM. This natural antibody pool controls to some extent S. pneumoniae bacteremia in unvaccinated mice [2] . We measured total serum IgM and anti-PC natural IgM levels in WT and CD73 KO mice. As shown in Fig 2A and 2B , no difference was observed between WT and CD73 KO mice. Because B-1 cells, especially the B-1b subset, have been shown to efficiently isotype switch to IgA-producing cells in vitro and in vivo [20, 21] , we also compared gut-associated IgA levels, but observed no difference between WT and CD73 KO mice (Panel A in S1 Fig) . Consistent with these results, no difference in survival was observed in WT versus CD73 KO mice following low-dose S. pneumoniae challenge (Fig 2C) . Taken together, our data strongly suggest preserved steady-state functions of B-1 B cells in CD73-deficient mice. Delayed IgM to IgG3 isotype switching but comparable susceptibility to S. pneumoniae challenge in CD73 KO mice following Pneumovax 23 vaccination Induced T cell independent IgG (especially IgG3 in mice) and IgM produced by innate B cells play an important role in the immune control of S. Pneumoniae [2, 18] . We therefore compared IgG3 and IgM production following Pneumovax 23 vaccination in WT and CD73 KO mice. We also compared the ability of vaccinated WT and CD73 KO mice to control S. pneumoniae infection. Antibody responses were measured against PPS3, a major component of the S. pneumoniae strain WU2 capsule [22] that is included in the Pneumovax 23 vaccine. As shown in Fig 3, vaccination of adult CD73 KO mice with Pneumovax 23 induced a slightly higher PPS3-specific IgM response and a lower IgG3 response compared to WT mice in the first week following vaccination. The anti-PPS3 IgG3 response however normalized at later time-points (Fig 3A and 3B) . These data thus indicated a delayed, yet effective, IgM to IgG3 isotype switching in CD73-deficient mice vaccinated with Pneumovax 23. To assess if this delay in isotype switching was associated to a decreased protective response, we challenged vaccinated mice with a lethal high-dose of S. pneumoniae. As shown in Fig 3C, survival rates in adult WT and CD73 KO mice were similar following challenge (Fig 3C) . Our data thus demonstrated that CD73 was not required for protective innate B cell antibody responses against S. pneumoniae.
IgG3 delay following Pneumovax 23 vaccination in A2aR KO mice
In order to test if the delay in Pneumovax induced IgG3 production in CD73 KO mice is a consequence of abrogated adenosine receptor engagement, we tested Pneumovax 23 antibody response in A2aR-deficient mice. The A2a receptor is ubiquitously expressed, and many biologic effects of adenosine, including the effect of adenosine on isotype switching during T cell dependent B cell responses [23, 24] are mediated via this receptor. A2aR-deficient mice show preserved frequencies and numbers of innate B-1 B cells (S2 Fig). Following Pneumovax 23 vaccination of A2aR KO mice we observed normal kinetics of PPS3 specific serum IgM but a delay of PPS3 specific IgG3 (Fig 4A and 4B) . To rule out the possibility that the IgG3 response is simply skewed toward toward another IgG isotype, we measured PPS3 specific IgG1, IgG2a and IgG2b, but did not detect any increase of these isotypes. In addition PPS3 specific IgA levels were similarly increased in serum of vaccinated A2aR KO mice (S3 Fig) . Similar to CD73 KO mice, PPS3 specific IgG3 serum levels were normal by 4 weeks, and A2aR-deficient mice were protected against a lethal live S. pneumoniae challenge (Fig 4C) . These results suggest that the delay of IgG3 production in CD73 KO mice is a consequence of impaired A2a receptor engagement, and show that A2a receptor is also not required for Pneumovax 23 induced protective innate B cell responses. Children under 2 years of age and young mice respond poorly to Pneumovax 23 vaccination [25] . Based on our observation that CD73 is poorly expressed on B-1 B cells in young mice and that CD73 and the A2aR promote isotype switching, we hypothesized that pharmacological agonists of the A2aR receptors may enhance the protective effects of Pneumovax 23 in this population. We thus investigated whether administration of an A2a adenosine receptor agonist (CGS 21680) could enhance antibody responses following Pneumovax 23 vaccination in young mice. As shown in Fig 5A and 5B, treatment with the A2a agonist significantly increased mean IgG3 levels at day 7 and 14 post-vaccination (Fig 5A and 5B) . Notably, this increase in IgG3 titers, although still lower than in vaccinated adult mice (Figs 5B and 3B and 4B) reflected a higher percentage of mice that responded to the vaccine (i.e. 6/10 mice in the CGS-treated group compared to 3/10 in the control group on day 28; Fig 5B) . We next challenged the vaccinated mice with a lethal high-dose of S. pneumoniae. Consistent with prior studies [23, 25] , vaccination of young WT mice with Pneumovax 23 failed to significantly protect them from S. pneumoniae infection. In contrast, co-administration of Pneumovax 23 and the A2a receptor agonist significantly increased survival of young mice compared to non-vaccinated mice ( Fig  5C) . Our study thus demonstrated that pharmacological activation of A2a adenosine receptor signaling is an effective means to promote class-switch recombination and enhance the protective effects of pneumococcal polysaccharide vaccination in young mice. 
Discussion
We here addressed the role of the adenosine-generating ecto-enzyme CD73 on innate B cell responses during streptococcal infections. Consistent with prior in vitro work that revealed a role for CD73 in class-switch recombination [14] , we demonstrated that CD73 promoted IgM to IgG3 isotype switching in mice vaccinated with Pneumovax 23. However, while CD73 expression accelerated IgG3 responses, CD73-deficient mice eventually mounted similar levels of antigen-specific IgG3 as WT mice. Hence, CD73 is not required for in vivo isotype switching, at least in response to Pneumovax 23. Our data further support correlative observations previously made in humans, where functionally compromised neonatal B cells were shown to lack CD73 expression [15] and adult isotype-switched B cells were shown to be enriched for CD73 + cells [14] .
Our observations using A2a-deficient KO mice suggest that the contribution of CD73 toward IgG3 production occurred through its enzymatic activity and through the engagement of the A2a receptor. Our data also indicate that delayed IgG3 production is not a consequence of skewing of IgG3 Ab response towards other IgG isotypes and that Pneumovax induced IgA production is not compromised.
The biologic basis of the isotype switch delay observed in CD73-deficient mice warrants further investigation. IgM to IgG3 class switch recombination is induced by synergistic BCR Ã : p<0.05; by One-way ANOVA; brackets are shown when significantly different from day 7 and 28 for a given group). (C) Survival of infected mice was monitored ( Ã : p<0.05 by log-rank test; survival was compared to non-vaccinated mice, unless indicated by a bracket; n.s: not significant).
and TLR signalling [26] , but is also modulated by cytokines, such as IL-21 [27] , at least in human B cells. Interestingly, IL-21 is known to upregulate CD73 on B and T cells [14] . Adenosine generated by CD73 has been shown to modulate cytokine production in macrophages [28] . It is possible that altered cytokine production lies at the heart of the isotype switch delay in CD73-deficient mice. Alternatively, since CD73 is known to be involved in the regulation of lymphocyte homing [29] , the lack of extracellular CD73-generated adenosine could also impact the homing of B-1 B cells to the spleen, which is a component of an efficient antibody response [3] . Proper homing of B cells to the marginal zone is regulated by the chemokines and chemokine receptors. Interestingly, adenosine has been proposed to modulate the CXCL12/CXCR4 axis [30] which may be relevant since B cell deficiency of CXCR4 leads to a decreased size of the marginal zone [29] as well as decreased TI antibody responses [31] . Alternatively, the CD73/A2a axis could regulate the rate of expansion of isotype switched B cells. Preliminary experiments assessing in vitro B-1 B cell IgG3 Ab production failed to show a difference between WT and CD73KO mice, suggesting an abnormal in-vivo niche for IgG3 producing cells in CD73KO mice. The observation that we could increase Pneumovax 23-induced IgG3 levels and improve protection against S. pneumoniae challenge by administering an A2a receptor agonist, suggests that modulation of the extracellular adenosine pathway is a potential avenue for increasing responsiveness to Pneumovax 23 in vulnerable populations, such as young infants and elderly. B cells in very young individuals show several deficiencies and are functionally compromised. B cells from newborns have very low levels of CD73 and low levels of the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI; receptor for BAFF and APRIL), which plays a key role in efficient antibody responses against polysaccharide vaccines [32] . Interestingly, recent studies demonstrated that A2a adenosine receptor negatively regulated isotype switched IgG1 germinal center (GC) responses [23] , likely via the suppression of T follicular helper cell differentiation [23, 24] . The impact of A2a receptor agonist treatment on antibody responses may thus vary depending on the cells that are targeted and mechanisms of B cell activation.
The introduction of pneumococcal conjugate vaccines (PCVs) has significantly reduced the incidence of invasive pneumococcal disease caused by vaccine included serotypes [33] , particularly in children. However, strains not included in the PCV vaccines still cause considerable disease, especially in susceptible populations. Therefore, administration of Pneumovax 23, which has a wider serotype coverage, is recommended in children and adults with conditions that put them at an increased risk of disease and in adults 65 years or older. For these individuals, optimization of anti-Pneumovax 23 vaccine response still remains a priority. The effect of CD73/A2a pathway modulation in the context of PCV however needs to be carefully assessed, as A2a agonist rather than antagonist has been described to enhance T cell dependent germinal center reactions (21) . Timing of PCV and Pneumovax 23 administration and of any adenosinergic pathway modulation may be critical. In conclusion, our study clarified the role of CD73 and the A2a adenosine receptor on innate B cell isotype-switching and identified A2a adenosine receptor as a potential target to enhance the protective activity of Pneumovax 23 against S. pneumoniae infections. Therapeutic targeting of A2a receptor could be attempted in combination with the targeting of additional pathways already known to modulate anti-Pneumovax 23 responses, such as PD-1 [22] , TLR [34] , or IL-7/IL7-R [25] . 
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